Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells.
about
Role of bile salt in regulating Mcl-1 phosphorylation and chemoresistance in hepatocellular carcinoma cellsAn Omics Perspective on Molecular Biomarkers for Diagnosis, Prognosis, and Therapeutics of CholangiocarcinomaThe significance of genetics for cholangiocarcinoma developmentGenetic profiling of intrahepatic cholangiocarcinomaProgression of targeted therapy in advanced cholangiocarcinomaThe role of the hepatitis viruses in cholangiocarcinomaIL-6 regulates Mcl-1L expression through the JAK/PI3K/Akt/CREB signaling pathway in hepatocytes: implication of an anti-apoptotic role during liver regenerationThe Bcl-2/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells.Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells.Endothelin-1 impairs nitric oxide signaling in endothelial cells through a protein kinase Cdelta-dependent activation of STAT3 and decreased endothelial nitric oxide synthase expression.Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2.Real-time PCR-based analysis of the human bile microRNAome identifies miR-9 as a potential diagnostic biomarker for biliary tract cancerCholangiocarcinoma: modern advances in understanding a deadly old diseasePlatelet-derived growth factor primes cancer-associated fibroblasts for apoptosis.PDGF upregulates Mcl-1 through activation of β-catenin and HIF-1α-dependent signaling in human prostate cancer cells.Cholangiocarcinoma: new insights into disease pathogenesis and biology.New insights on cholangiocarcinoma.FTY720 inhibits proliferation and epithelial-mesenchymal transition in cholangiocarcinoma by inactivating STAT3 signalingPathogenesis, diagnosis, and management of cholangiocarcinomaCholangiocarcinoma: molecular pathways and therapeutic opportunitiesEts-1 mediates upregulation of Mcl-1 downstream of XBP-1 in human melanoma cells upon ER stress.IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6-sensitive mechanismThe Prognostic Role of SOCS3 and A20 in Human CholangiocarcinomaInterleukin-6-driven progranulin expression increases cholangiocarcinoma growth by an Akt-dependent mechanismLiver regeneration is suppressed in alcoholic cirrhosis: correlation with decreased STAT3 activationInterleukin-6 and its receptor, key players in hepatobiliary inflammation and cancerJAK-STAT pathway in carcinogenesis: is it relevant to cholangiocarcinoma progression?Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing.The challenge of cholangiocarcinoma: dissecting the molecular mechanisms of an insidious cancer.Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.A Hippo and Fibroblast Growth Factor Receptor Autocrine Pathway in CholangiocarcinomaGenomic dissection of the cytokine-controlled STAT5 signaling network in liverCholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment.Leptin enhances cholangiocarcinoma cell growthAKT and ERK1/2 signaling in intrahepatic cholangiocarcinoma.Genome-wide screen identified let-7c/miR-99a/miR-125b regulating tumor progression and stem-like properties in cholangiocarcinomaModulation of PKCdelta signaling alters the shear stress-mediated increases in endothelial nitric oxide synthase transcription: role of STAT3.Mechanisms of biliary carcinogenesis and growthAntitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells.Expression of phospho-ERK1/2 and PI3-K in benign and malignant gallbladder lesions and its clinical and pathological correlations.
P2860
Q24300062-6B15421F-9501-47A4-8DF0-4AF58D160E92Q26784091-2892F1B1-25C7-49C5-A3F7-EDF2E9F7874FQ26865749-6BF4C412-0F40-483D-A284-D17B3B96F89AQ27005787-E60BCA73-D718-457B-A328-CAF18FFE48B4Q27016150-CF205627-33B5-4A86-8EE4-E7C7ED27D054Q28288613-5D6D1C92-A6E6-48A7-B998-4D6723F8EC26Q28534312-71AF66B3-AD8C-4D8E-ADD6-F0CAECAE3C89Q33612421-F63F7798-BE88-4CBD-AE4C-411CF27B6D57Q33645250-15E97A6D-ECBC-4EFB-BE3D-2B49FA4B1E7FQ33892724-30C9E719-2751-44E5-B44E-8D718F535B3CQ33936548-DCE0CC0C-7648-4D2D-9CF8-243517BCEE93Q33999840-965DDAB9-66C0-4C8D-9F25-EF4DB0188153Q34000079-94D1DFE0-0375-401D-BE07-C757362E8193Q34044638-C7EBE279-2711-487D-8677-7033029A4C36Q34140712-D0CFDFAB-B42A-43BB-B145-37E7D793FEA6Q34194655-7FB554BE-51B1-4550-870C-AB20CC936418Q34391135-2E9A1734-E610-46FE-9D27-BD79725036CCQ34459845-8147778E-74AA-4EC6-82E5-B8CA5996F005Q34656747-3F576C6B-EEA6-4B28-A826-2EEC6D737345Q34959174-39F17BD7-73AC-4091-BF73-2D3F31EB044AQ35185157-8F264E5F-BB3B-45D8-9EC5-B0C8E4E8164EQ35528356-1A75E5CD-DE5B-43C0-B289-C84CA1B9D609Q35814659-20578C6F-D043-4A01-8FB8-564FC5CD9E03Q35841978-C2E9E397-D06D-40AE-970D-AD195B4BF815Q36003091-92CB54E3-1A2F-44EB-A7B8-8C7881EF5DCAQ36042724-5137960A-7C93-4DDF-A907-8FE5FCBA2557Q36178175-E318FD7B-B18C-4A66-865B-7484618F7F4DQ36388792-AF5884D1-38DD-4D13-BF69-84977DE34C80Q36683019-6FF84F1E-9135-4CBF-A851-7FFABF88A6CDQ36759538-3FA3866F-C9A9-4385-926A-E3A34A0B4960Q36778814-B53204EE-743C-40C5-9E02-CD329696B04AQ36808291-46767FA6-F105-4987-AE00-241701BED670Q36900063-415FF621-A378-4ACC-A6C9-29CF4A976625Q36915317-DD77962E-7BCB-4590-B722-A65E1F145CBBQ37045823-019DA24C-78CD-4C98-A60A-6502C8D817C8Q37064043-ABC3BEE9-83D1-4BA7-B9E8-C34F69D4E4D2Q37138906-3B087DB1-8324-42DD-9A7D-CF5C52DD533AQ37169351-38995D85-C2B4-457F-8A1F-0D271EAB95E9Q37190258-59DEE1D2-E995-40A7-8DD5-310ED61C90BDQ37215137-3B71F682-A507-4CF5-9E0B-B537ECCB4CEF
P2860
Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Interleukin 6 upregulates myel ...... y in cholangiocarcinoma cells.
@en
type
label
Interleukin 6 upregulates myel ...... y in cholangiocarcinoma cells.
@en
prefLabel
Interleukin 6 upregulates myel ...... y in cholangiocarcinoma cells.
@en
P2093
P2860
P356
P1433
P1476
Interleukin 6 upregulates myel ...... y in cholangiocarcinoma cells.
@en
P2093
David A Frank
Hajime Isomoto
Maria Eugenia Guicciardi
Nathan W Werneburg
Shogo Kobayashi
Steve F Bronk
P2860
P304
P356
10.1002/HEP.20966
P407
P577
2005-12-01T00:00:00Z